Alpha 2.0
Login Register
» Articles » PMID: 38722534

Challenges of Diagnosing Homologous Recombination Deficiencies in Metastatic Prostate Cancer: a Six-year Experience from a Single Institution

Overview
Journal Clin Transl Oncol
Specialty Oncology
Date 2024 May 9
PMID 38722534
Authors
Javier Gavira
Jose Carlos Tapia
Alejandra Romano
Georgia Anguera
Maria Aguado
Aida Piedra
Freya Bosma
Sofia Sanchez
Cristina Martin
Ferran Algaba
Yolanda Arce
Teresa Ramon Y Cajal
Pablo Maroto
Affiliations
Soon will be listed here.
Abstract

Purpose: We evaluated the prevalence of homologous recombination deficiencies (HRD) to determine the efficacy of different techniques and clinical characteristics of patients.

Methods: This retrospective study included patients with metastatic prostate cancer who underwent molecular testing at our hospital between 2016 and 2022. We used tumor tissue, ctDNA, and lymphocytes for somatic or germline testing. We analyzed the clinical characteristics and survival outcomes.

Results: 144 patients were tested (113 somatic, 21 germline, and 10 both). Technical issues prevented the analysis of 23 prostatic samples (18.7%). 12 (8.3%) patients had HRD. BRCA2 was the most frequent mutation (66.7%). Patients with HRD were younger (57.5 years). Patients with BRCA mutations had poorer survival (31.9 vs 56.3 months, p = 0.048).

Conclusion: In our institution, 8.3% of the patients had HRD. Tumor tissue analysis failed in 18.7% of tests. ctDNA analysis is an alternative detection method. BRCA mutations are correlated with poor prognosis.

References
1.
Flippot R, Patrikidou A, Aldea M, Colomba E, Lavaud P, Albiges L . PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer. Drugs. 2022; 82(7):719-733. DOI: 10.1007/s40265-022-01703-5. View
2.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 382(22):2091-2102. DOI: 10.1056/NEJMoa1911440. View
3.
Fizazi K, Piulats J, Reaume M, Ostler P, McDermott R, Gingerich J . Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023; 388(8):719-732. PMC: 10064172. DOI: 10.1056/NEJMoa2214676. View
4.
Pascual J, Attard G, Bidard F, Curigliano G, De Mattos-Arruda L, Diehn M . ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022; 33(8):750-768. DOI: 10.1016/j.annonc.2022.05.520. View
5.
Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J . PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019; 37(6):490-503. DOI: 10.1200/JCO.18.00358. View